StimCardio applies peripheral neuromodulation to a cardiology problem rather than a neurological one, using the autonomic nervous system as the lever on arrhythmia burden and positioning Rhyvive as an adjunct to ablation rather than a replacement for it. Randomized, sham-controlled NeuroPulse results published in Heart Rhythm give it a level of clinical evidence uncommon among wearable neuromodulation companies, with regulatory clearance still ahead.